Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
…, É Radeczky, J Schlezák, E Springer… - The Lancet …, 2017 - thelancet.com
Background Benralizumab is a humanised, anti-interleukin 5 receptor α monoclonal
antibody that directly and rapidly depletes eosinophils, reduces asthma exacerbations, and …
antibody that directly and rapidly depletes eosinophils, reduces asthma exacerbations, and …
The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD
AM Kirsten, K Förster, E Radeczky, A Linnhoff… - Pulmonary …, 2015 - Elsevier
Background Chronic obstructive pulmonary disease (COPD) is characterized by neutrophil-dominated
airway mucosal inflammation and elevated neutrophil counts in sputum and lung …
airway mucosal inflammation and elevated neutrophil counts in sputum and lung …
Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible …
A Lindberg, Z Szalai, T Pullerits, E Radeczky - Respirology, 2007 - Wiley Online Library
Background and objectives: Data on the onset of action of COPD medications are lacking.
This study compared the onset of bronchodilation following different inhaled therapies in …
This study compared the onset of bronchodilation following different inhaled therapies in …
The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD
AM Kirsten, K Förster, E Radeczky, A Linnhoff, B Balint… - 2012 - Eur Respiratory Soc
BACKGROUND: This Phase IIa study evaluated the safety and tolerability of the CXCR2
antagonist AZD5069 in patients with moderate-to-severe COPD. METHODS: This was a 4-week…
antagonist AZD5069 in patients with moderate-to-severe COPD. METHODS: This was a 4-week…
Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses
…, M Engel, N Tudoric, B Forstner, E Radeczky… - 2013 - Eur Respiratory Soc
Background: Tiotropium, a once-daily long-acting anticholinergic bronchodilator, improved
lung function and reduced severe exacerbations in patients with severe symptomatic asthma …
lung function and reduced severe exacerbations in patients with severe symptomatic asthma …
Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin
TM Behr, N Jenner, S Radetzky, M Béhe… - European journal of …, 1998 - Springer
The outstanding sensitivity of pentagastrin in detecting the presence of primary, recurrent or
metastatic medullary thyroid cancer (MTC) suggests widespread expression of the …
metastatic medullary thyroid cancer (MTC) suggests widespread expression of the …
Activin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression
…, N Mitsiades, FE Kruse, S Radetzky, E Iliaki… - The American journal of …, 2004 - Elsevier
Activin A, a dimeric glycoprotein that belongs to the transforming growth factor-β superfamily,
governs cellular differentiation in a wide variety of models and has been implicated in the …
governs cellular differentiation in a wide variety of models and has been implicated in the …
Lung transplant patients on Kilimanjaro
B Gieszer, P Radeczky, A Farkas, K Csende… - Transplantation …, 2019 - Elsevier
… Author links open overlay panel Balázs Gieszer a b , Péter Radeczky a b , Attila Farkas a
b , Kristóf Csende a , László Mészáros a b , Klára Török a b , Levente Fazekas b c , Levente …
b , Kristóf Csende a , László Mészáros a b , Klára Török a b , Levente Fazekas b c , Levente …
[HTML][HTML] Pathological but not physiological retinal neovascularization is altered in TNF-Rp55-receptor–deficient mice
N Kociok, S Radetzky, TU Krohne… - … & visual science, 2006 - arvojournals.org
… The ang-1 mean normalized mRNA expression in the wild type was determined with 1.5E−05
± 1.5E−06. The ang-1 mRNA expression was only slightly increased in Rp55 −/− mice but …
± 1.5E−06. The ang-1 mRNA expression was only slightly increased in Rp55 −/− mice but …
[HTML][HTML] Current therapy of KRAS-mutant lung cancer
A Ghimessy, P Radeczky, V Laszlo, B Hegedus… - Cancer and Metastasis …, 2020 - Springer
KRAS mutations are the most frequent gain-of-function alterations in patients with lung
adenocarcinoma (LADC) in the Western world. Although they have been identified decades ago, …
adenocarcinoma (LADC) in the Western world. Although they have been identified decades ago, …